Physician profile
Paraskos Araouzos
NPI 1316938830
$2,143.38
in general payments reported to CMS, 2019-2025
23 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $81.61 · 2023: $252 · 2024: $566 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $266.53 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $250.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $235.62 | 2023-2025 | |
| Abbvie INC. | $181.52 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $146.56 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $138.05 | 2023-2025 | |
| Kyowa Kirin, INC. | $130.95 | 2025 | |
| Amgen INC. | $111.53 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $107.55 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.77 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $97.68 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $91.27 | 2019-2025 | Airsupra |
| Amneal Pharmaceuticals LLC | $47.77 | 2024-2025 | Unithroid |
| Amarin Pharma, INC. | $41.90 | 2019-2020 | |
| Ibsa Pharma INC. | $31.37 | 2023-2025 | Tirosint, Tirosint, Flector |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $25.51 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $24.89 | 2019 | |
| Abbott Laboratories | $24.81 | 2023 | Freestyle Libre 3 |
| Seqirus USA INC | $21.10 | 2025 | Fluad, Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.22 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $18.06 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2024 | Trulance, Xifaxan |
| Genentech USA, INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paraskos Araouzos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.